Altimmune, Inc.
About Altimmune, Inc.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $41.0K
- Net income
- -$88.1M
- Total assets
- $279.9M
- Market cap
- $527.0M
- Operating margin
- -230461.0%
- Net margin
- -214861.0%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $41.0K
- Operating expenses
- $94.5M
- Operating income
- -$94.5M
- Income tax
- -$681.0K
- Net income
- -$88.1M
- EPS (basic)
- $-1.00
- EPS (diluted)
- $-1.00
Balance sheet
- Total assets
- $279.9M
- Current assets
- $278.2M
- Total liabilities
- $55.0M
- Current liabilities
- $15.0M
- Shareholders’ equity
- $224.9M
Cash flow
- Operating cash flow
- -$67.5M
- Investing cash flow
- -$132.5M
- Financing cash flow
- $206.8M
- Net cash flow
- $6.8M
Statements via Polygon.io (SEC filings)
- Market cap
- $527.0M
- EPS (diluted)
- $-1.0
- Shares outstanding
- 193.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 6, 2005
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $88.1M in FY2025.
- Revenue declined 99% from FY2020 to FY2025.
- Trading 65% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Altimmune, Inc..
Write a review
News about Altimmune, Inc.
News & sentiment via Polygon.io
